NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock

NeuroOne Medical Technologies

Corporation Announces Proposed Public Offering of Common Stock

PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the "Company"),

a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders,

announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.

All of the shares of common stock to be sold

in the proposed offering will be sold by the Company. In addition, the Company intends to

grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The

proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,

or as to the actual size or terms of the offering.

Company intends to use the proceeds from this proposed offering to: (i) support the commercial launch of the EVO sEEG electrode with Zimmer

Biomet, (ii) support the FDA submission for the OneRF ablation system and (iii) complete the design of a novel drug delivery electrode,

among other general corporate purposes.

The Benchmark Company, LLC is acting as sole

book-running manager for the proposed offering. Kestrel Merchant Partners group at The Benchmark Company, LLC is responsible for sourcing

and executing the offering.

The proposed offering is being made pursuant

to a shelf registration statement on Form S-3 (File No. 333-256830) that was declared effective by the U.S. Securities and Exchange Commission

("SEC"), on June 14, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering

will be filed with the SEC and will be available on the SEC's website at www.sec.gov or by contacting The Benchmark Company, LLC,

150 East 58th St., 17th Floor, New York, NY 10155, by telephone at 212-312-6700 or by email at prospectus@benchmarkcompany.com.

This press release does not and shall not

constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in

any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under

the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including

a prospectus supplement, forming a part of the effective registration statement.

NeuroOne Medical Technologies Corporation

is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation

and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed

back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may

also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.

Forward Looking Statements

This press release may include forward-looking

statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act

of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward-looking

statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and

other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information

expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words

"may," "might," "will," "could," "would," "should," "expect," "intend,"

"plan," "objective," "anticipate," "believe," "estimate," "predict," "project,"

"potential," "target," "seek," "contemplate," "continue" and "ongoing," or

the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements

include statements related to the proposed offering and expected use of proceeds. Although the Company believes that we have a reasonable

basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently

known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different

from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions,

the satisfaction of customary closing conditions related to the proposed public offering, the impact of general economic, industry or

political conditions in the United States or internationally and those described under the heading "Risk Factors" in our filings

with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release and

the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information

becomes available in the future.